Mikhail Kosiborod, MD, Vice President of Research at Saint Luke's Health System, cardiologist at Saint Luke's Mid America Heart Institute, and the principal investigator of PRESERVED-HF outlines the findings from the PRESERVED-HF trial, demonstrating that dapagliflozin improves symptoms and physical function in people with heart failure with preserved ejection fraction, and discusses the promise of SGLT2 inhibitors for meeting the treatment goals in this population. 

The findings of the PRESERVED-HF trial, which offers potential new hope for people struggling with heart failure with preserved ejection fraction (HFpEF), were published on October 28, 2021, in the journal Nature Medicine.

Listen to the full interview with Medicine Matters: PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status.